Screener
Adaptive Biotechnologies ADPT Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $71.55M+21.5% | $70.87M+35.1% | $71.68M+51.0% | $93.97M+102% | $58.88M+36.3% | ||
| $20.17M+12.0% | $18.71M+10.2% | $18.22M+1.0% | $18.16M+8.9% | $18M-6.8% | ||
| $51.39M+25.7% | $52.17M+47.1% | $53.46M+81.7% | $75.82M+155% | $40.88M+71.2% | ||
| 71.8%+2.4pp | 73.6%+6.0pp | 74.6%+12.6pp | 80.7%+16.6pp | 69.4%+14.2pp | ||
| $19.15M-20.6% | $23.62M-2.4% | $21.76M-6.2% | $23.67M-2.0% | $24.13M-4.8% | ||
| $26.41M+12.1% | $26.35M+14.3% | $24.48M+13.5% | $23.47M+14.2% | $23.57M+16.0% | ||
| $21.17M+19.0% | $20.98M+20.6% | $19.56M+8.3% | $17.96M+4.1% | $17.79M-0.6% | ||
| $87.32M+4.1% | $90.08M+9.8% | $84.45M+3.9% | $83.68M+5.8% | $83.92M-7.3% | ||
| -$15.77M+37.0% | -$19.21M+35.1% | -$12.77M+62.3% | $10.29M+132% | -$25.04M+47.1% | ||
| -22%+20.5pp | -27.1%+29.4pp | -17.8%+53.5pp | 10.9%+81.2pp | -42.5%+67.0pp | ||
| -$39.79M-55.3% | -$20.03M+32.9% | -$13.58M+59.7% | $9.55M+130% | -$25.61M+44.6% | ||
| -55.6%-12.1pp | -28.3%+28.7pp | -18.9%+52.0pp | 10.2%+79.2pp | -43.5%+63.5pp | ||
| -$0.25-47.1% | -$0.13+35.0% | -$0.09+59.1% | $0.06+127% | -$0.17+45.2% | ||
| -$12.08M+41.2% | -$15.37M+38.2% | -$8.58M+70.8% | $14.7M+152% | -$20.53M+51.5% | ||
| -16.9%+18.0pp | -21.7%+25.7pp | -12%+50.0pp | 15.6%+76.0pp | -34.9%+63.1pp | ||
| -$15.77M+37.0% | -$19.21M+35.1% | -$12.77M+62.3% | $10.29M+132% | -$25.04M+47.1% |
FAQ
- What is Adaptive Biotechnologies's revenue?
- Adaptive Biotechnologies (ADPT) generated $308.1M in revenue over the trailing twelve months, up 50.1% year over year.
- Is Adaptive Biotechnologies profitable?
- Adaptive Biotechnologies is not currently profitable: it reported a net loss of $63.9M over the trailing twelve months, a -20.7% net margin.
- What are Adaptive Biotechnologies's profit margins?
- Gross margin is 75.6% and operating margin is -12.2%, with a -20.7% net margin.
- What is Adaptive Biotechnologies's earnings per share?
- Adaptive Biotechnologies's diluted EPS over the trailing twelve months is $-0.41.
- Where does Adaptive Biotechnologies's income statement data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
